Nasiri Hajar, Manoochehrabadi Tahereh, Eskandari Fatemeh, Majidi Jila, Gholipourmalekabadi Mazaher
Department of Tissue Engineering and Applied Cell Sciences, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
Department of Tissue Engineering & Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mol Biol Rep. 2025 May 24;52(1):501. doi: 10.1007/s11033-025-10570-8.
Mesenchymal stem cells (MSCs) have emerged as a promising option for gene and cell therapy due to their unique biological properties. MSC-based cell therapies have garnered significant attention for various clinical applications; however, repeated administrations are often necessary to achieve sustained therapeutic effects. Genetic modification techniques have enhanced MSCs' intrinsic capabilities, improving their therapeutic efficacy in both experimental and clinical settings. Key functional properties anti-inflammatory, anti-fibrotic, survival, and migratory capacities have become central targets for genetic enhancement. Numerous studies have explored the genetic modification of MSCs to address overcoming the transient nature of their therapeutic effects. Notably, the safety of genetically engineered MSCs remains a critical concern in preclinical and clinical investigations.In this review, we summarize current strategies for the genetic modification of MSCs and discuss recent findings on their application in animal disease models.
间充质干细胞（MSCs）因其独特的生物学特性，已成为基因治疗和细胞治疗的一个有前景的选择。基于MSCs的细胞疗法在各种临床应用中已引起广泛关注；然而，通常需要重复给药才能实现持续的治疗效果。基因改造技术增强了MSCs的内在能力，提高了它们在实验和临床环境中的治疗效果。关键的功能特性，如抗炎、抗纤维化、存活和迁移能力，已成为基因增强的核心靶点。许多研究探索了对MSCs进行基因改造，以解决其治疗效果的短暂性问题。值得注意的是，基因工程化MSCs的安全性在临床前和临床研究中仍然是一个关键问题。在这篇综述中，我们总结了目前MSCs基因改造的策略，并讨论了它们在动物疾病模型中应用的最新研究结果。
